Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Trending topics among doctors today!
Trending topics among doctors today!
As few as about 2,600 and about 2,800 steps/day yielded significant mortality and cardiovascular disease benefits, in a study published in the Journal of the American College of Cardiology. Progressive risk reductions were observed up to an optimal 7,200 steps/day…
In the Phase IIIb HARMONIE trial, nirsevimab (Beyfortus) drastically reduced infant respiratory syncitial virus (RSV) hospitalisations by 83%, and reduced all-cause lower respiratory tract infection hospitalisations by 58% (n = 8058). RSV is the most common cause of respiratory tract…
In the Phase III INSPIRES trial, clopidogrel-aspirin led to a lower risk of new stroke at 90 days than aspirin alone (7.3% vs. 9.2%, p = 0.008), in patients with mild ischemic stroke or high-risk transient ischemic attack of presumed…
The FDA has issued an update to the ciltacabtagene autoleucel (CARVYKTI) label describing secondary AML/MDS in 10% of patients treated on CARTITUDE-1 (10/97). CARTITUDE-1 is a Phase IB/II trial that evaluated ciltacabtagene autoleucel (CARVYKTI) in patients with relapsed of refractory…
In a cross-sectional study of 2775 patients with colorectal cancer from 2011 to 2016, decreased use of neoadjuvant radiotherapy (87% to 37%) was not associated with changes in 4-year local recurrence (5.8% vs 5.5%) in patients with lower risk rectal…
A new structural class of antibiotics has been discovered using deep learning-guided exploration of chemical spaces. The last one took 38 years! The article published in Nature identified compounds with efficacy against multiple bacteria (without toxicity), including methicillin-resistant Staphylococcus aureus…
177Lu-PNT2002 met its primary endpoint of radiographic progression-free survival (rPFS) in the pivotal Phase III SPLASH trial (9.5 months vs 6.0 months, HR 0.71), in patients with metastatic castration-resistant prostate cancer (mCRPC) after progression on an androgen receptor pathway inhibitor…
